Clinical Trials
16 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07377487 2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT06881992 2026-05-18
Tumor HI
Rezolute
Phase 3 Recruiting
NCT02402244 2026-05-05
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
Recruiting
NCT06502977 2026-04-15
DeLLphi-307
Amgen
Phase 2 Active not recruiting
NCT07404176 2026-02-11
TENET
Tata Memorial Hospital
Phase 2 Recruiting
NCT03600233 2025-12-23
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
Phase 2 Active not recruiting
NCT07262970 2025-12-04
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
Available
NCT07258810 2025-12-02
ETP-NET
Hospices Civils de Lyon
Not yet recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT06577987 2025-09-15
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
Phase 1 Recruiting
NCT06908629 2025-08-26
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Barbara Ann Karmanos Cancer Institute
Phase NA Recruiting
NCT04837885 2025-07-23
LUTARTERIAL
University Hospital, Bordeaux
Phase 2 Recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02279433 2025-06-24
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
Phase 1 Completed
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated